Hepatitis B
Lymphoma Chemotherapy Can Cause Severe Hepatitis B Reactivation
- Details
- Category: HBV-Related Conditions
- Published on Tuesday, 28 September 2010 12:46
- Written by Liz Highleyman
Chronic hepatitis B patients are at risk for recurrence or relapse when they undergo chemotherapy for lymphoma, despite receiving prophylaxis with lamivudine (Epivir-HBV), according to an Italian study presented at the recent 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2010) in Boston. Investigators recommended that other potentially more effective antiviral drugs should be studied for this indication.
Nearly 20% of New Hepatitis B Infections May Occur in Healthcare Settings
- Details
- Category: HBV Prevention
- Published on Friday, 24 September 2010 12:46
- Written by Liz Highleyman
As many as 1 in 5 cases of acute hepatitis B virus (HBV) infection in the U.S. may be attributable to exposure in healthcare settings, especially long-term care facilities, according to research presented last week at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2010) in Boston.
Flares during HBV Treatment Do Not Predict Response, May Cause Liver Failure
- Details
- Category: HBV Treatment
- Published on Sunday, 12 September 2010 00:00
- Written by Liz Highleyman
Developing hepatic flares, or sudden increases in liver enzymes or viral load, while undergoing nucleoside/nucleotide analog therapy for chronic hepatitis B did not increase the likelihood of sustained viral clearance and led to decompensated liver failure in some patients, researchers reported in the July 2011 Journal of Viral Hepatitis.
Androgen Receptor May Explain Why More Men with Hepatitis B Develop Liver Cancer
- Details
- Category: HBV Disease Progression
- Published on Tuesday, 21 September 2010 12:49
- Written by University of Rochester
Androgen receptors -- proteins on cell surfaces that bind with male hormones like testosterone -- interact directly with hepatitis B virus (HBV) to turn on genes that trigger cell changes leading to liver cancer, according to a study published in the May 19, 2010 issue of Science Translational Medicine. Because androgen receptors are more active in men, this finding helps explain why men with chronic hepatitis B are about 3 times more likely than women to develop hepatocellular carcinoma.
Adding Adefovir Works Better than Entecavir Monotherapy for Lamivudine-resistant Hepatitis B Patients
- Details
- Category: HBV Treatment
- Published on Friday, 27 August 2010 12:49
- Written by Liz Highleyman
Addition of adefovir (Hepsera) to lamivudine (Epivir-HBV) proved to be a better "rescue therapy" strategy for patients with lamivudine-resistant hepatitis B virus (HBV) than switching to entecavir (Baraclude) monotherapy, according to a South Korean study published in the August 2010 Journal of Gastroenterology and Hepatology.
Pegylated Interferon Has Low Sustained Response Rate in HBeAg Negative Chronic Hepatitis B Patients
- Details
- Category: HBV Treatment
- Published on Friday, 17 September 2010 12:49
- Written by Liz Highleyman
Only about 1 in 5 patients with hepatitis B "e" antigen (HBeAg) negative chronic hepatitis B achieved sustained response to treatment with pegylated interferon, and about half that many reached undetectable HBV viral load, according to a study published in the August 2010 American Journal of Gastroenterology. Addition of ribavirin -- which helps prevent relapse in people with chronic hepatitis C -- did not significantly improve response rates.
Hepatitis B Virus Infection Linked to Non-Hodgkin Lymphoma in South Korean Study
- Details
- Category: HBV-Related Conditions
- Published on Friday, 06 August 2010 12:49
- Written by Liz Highleyman
People with chronic hepatitis B virus (HBV) infection were almost twice as likely as uninfected individuals to develop non-Hodgkin lymphoma and certain other types of blood cell cancers, according to a large South Korean analysis described in the August 4, 2010 advance online edition of Lancet Oncology. Occurrence of lymphoma was uncommon overall, however, indicating that prevention and treatment of hepatitis B is unlikely to greatly affect lymphoma rates.
Long-term Entecavir Leads to Regression of Liver Fibrosis in Chronic Hepatitis B Patients
- Details
- Category: HBV Treatment
- Published on Tuesday, 14 September 2010 12:49
- Written by Liz Highleyman
Chronic hepatitis B treatment using entecavir (Baraclude) for 1 year is good, but 3 years is better, according to an international study published in the September 2010 issue of Hepatology. Patients who received at least 3 years of cumulative entecavir therapy showed substantial histological improvement on liver biopsies and experienced regression of liver fibrosis or cirrhosis.
High HBV Viral Load and HBeAg Positive Status Increase Risk of Mother-to-child Hepatitis B Transmission Despite Vaccine
- Details
- Category: HBV Prevention
- Published on Friday, 16 July 2010 12:49
- Written by Liz Highleyman
Women with hepatitis B virus (HBV) infection who were hepatitis B "e" antigen (HBeAg) positive and had high HBV DNA viral load during pregnancy were more likely to transmit the virus to their infants, even though the babies received HBV prophylaxis, according to a Canadian study described in the June 11, 2010 advance online edition of the Journal of Viral Hepatitis.
More Articles...
- Is Routine Hepatitis B Screening Necessary Before Starting Cancer Chemotherapy?
- U.S. Hepatitis B Prevalence in the U.S. in the HBV Vaccine Era
- How Long Do Chronic Hepatitis B Patients Need to be Treated to Sustain HBeAg Seroconversion?
- Sex Hormone Receptor May Explain Higher Risk of Hepatocellular Carcinoma in Men
- Safety Review Clears Continuation of Hepislav Hepatitis B Vaccine
Web Design and Development by